Discrimination of Cancer Stem Cell Markers ALDH1A1, BCL11B, BMI-1, and CD44 in Different Tissues of HNSCC Patients.
Aldehyde Dehydrogenase 1 Family
/ genetics
Head and Neck Neoplasms
/ genetics
Humans
Hyaluronan Receptors
/ genetics
Neoplastic Stem Cells
Polycomb Repressive Complex 1
/ genetics
Repressor Proteins
/ genetics
Retinal Dehydrogenase
/ genetics
Squamous Cell Carcinoma of Head and Neck
/ genetics
Tumor Suppressor Proteins
/ genetics
CSCs
HNSCC
histopathology
lymph node
mucosa
tumor
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
19 07 2021
19 07 2021
Historique:
received:
31
05
2021
revised:
03
07
2021
accepted:
11
07
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Cancer stem cells (CSCs) are accountable for the progress of head and neck squamous cell carcinoma (HNSCC). This exploratory study evaluated the expression of molecular CSC markers in different tissues of HNSCC patients. Tissue specimens of primary tumor, lymph node metastases and macroscopically healthy mucosa of 12 consecutive HNSCC patients, that were treated with surgery and adjuvant radio(chemo)therapy upon indication, were collected. Samples were assessed for the expression of p16 as a surrogate for HPV-related disease and different molecular stem cell markers (ALDH1A1, BCL11B, BMI-1, and CD44). In the cohort, seven patients had HPV-related HNSCC; six thereof were oropharyngeal squamous cell carcinoma. While expression of BMI-1 and BCL11B was significantly lower in healthy mucosa than both tumor and lymph node metastasis, there were no differences between tumor and lymph node metastasis. In the HPV-positive sub-cohort, these differences remained significant for BMI-1. However, no significant differences in these three tissues were found for ALDH1A1 and CD44. In conclusion, this exploratory study shows that CSC markers BMI-1 and BCL11B discriminate between healthy and cancerous tissue, whereas ALDH1A1 and CD44 were expressed to a comparable extent in healthy mucosa and cancerous tissues.
Identifiants
pubmed: 34287293
pii: curroncol28040241
doi: 10.3390/curroncol28040241
pmc: PMC8293237
doi:
Substances chimiques
BCL11B protein, human
0
BMI1 protein, human
0
CD44 protein, human
0
Hyaluronan Receptors
0
Repressor Proteins
0
Tumor Suppressor Proteins
0
Aldehyde Dehydrogenase 1 Family
EC 1.2.1
ALDH1A1 protein, human
EC 1.2.1.36
Retinal Dehydrogenase
EC 1.2.1.36
Polycomb Repressive Complex 1
EC 2.3.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2763-2774Références
Transl Oncol. 2021 Jan;14(1):100906
pubmed: 33075658
Acta Otolaryngol. 2016;136(5):501-5
pubmed: 27052966
Cancer Res. 2015 Feb 1;75(3):480-6
pubmed: 25589349
Front Immunol. 2015 Apr 08;6:154
pubmed: 25904917
PLoS One. 2008;3(10):e3360
pubmed: 18852874
Stem Cell Rev Rep. 2018 Dec;14(6):769-784
pubmed: 30076557
Cancer Med. 2019 Apr;8(4):1908-1918
pubmed: 30821126
Oncotarget. 2015 Apr 20;6(11):8807-21
pubmed: 25871396
Anticancer Res. 2020 Apr;40(4):2117-2123
pubmed: 32234904
J Oral Pathol Med. 2014 Aug;43(7):499-506
pubmed: 24527751
Lab Invest. 2014 Dec;94(12):1431-45
pubmed: 25286028
Pathol Int. 2012 Oct;62(10):684-9
pubmed: 23005595
N Engl J Med. 2015 Feb 26;372(9):793-5
pubmed: 25635347
Laryngoscope. 2009 Aug;119(8):1518-30
pubmed: 19507218
Oral Oncol. 2014 Dec;50(12):1144-8
pubmed: 25264224
Cancer Med. 2013 Aug;2(4):507-18
pubmed: 24156023
Semin Oncol. 1994 Jun;21(3):281-8
pubmed: 8209260
Lancet Oncol. 2016 Apr;17(4):440-451
pubmed: 26936027
J Oncol. 2011;2011:
pubmed: 20936121
Head Neck. 2012 Jan;34(1):42-9
pubmed: 21322081
PLoS One. 2009;4(4):e5367
pubmed: 19399189
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Recent Results Cancer Res. 2017;206:233-242
pubmed: 27699543
J Oral Pathol Med. 2018 Sep;47(8):740-747
pubmed: 29791975
Science. 2009 Jun 26;324(5935):1670-3
pubmed: 19556499
J Clin Oncol. 2008 Jun 10;26(17):2871-5
pubmed: 18539966
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8
pubmed: 17210912
Oral Oncol. 2017 Oct;73:88-96
pubmed: 28939082
J Cell Physiol. 2020 Jan;235(1):65-73
pubmed: 31206697
Contrast Media Mol Imaging. 2017 Jun 20;2017:2709547
pubmed: 29097914
Ann Oncol. 2010 Oct;21(10):1931-1934
pubmed: 20716626
Stem Cells Int. 2013;2013:319489
pubmed: 23533441
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):461-8
pubmed: 26867875
Clin Cancer Res. 2015 Feb 15;21(4):870-81
pubmed: 25492084
Oral Oncol. 2008 Sep;44(9):823-9
pubmed: 18203652
Diagn Pathol. 2014 Nov 29;9:221
pubmed: 25432701
Oral Oncol. 2012 Jan;48(1):1-9
pubmed: 22070916
Histopathology. 2012 Dec;61(6):1089-105
pubmed: 22882088
PLoS One. 2017 Nov 7;12(11):e0187615
pubmed: 29112953
Clin Cancer Res. 2016 Jun 1;22(11):2639-49
pubmed: 26755529
Sci Rep. 2017 Feb 21;7:43008
pubmed: 28220856
Br J Cancer. 2006 Nov 20;95(10):1432-8
pubmed: 17003776
Ann Transl Med. 2016 Dec;4(24):518
pubmed: 28149880
Methods Mol Biol. 2009;568:175-93
pubmed: 19582427
Clin Transl Radiat Oncol. 2016 Dec 22;1:19-26
pubmed: 29657990
Oncotarget. 2017 Apr 10;8(32):52345-52356
pubmed: 28881734
Clin Cancer Res. 2010 Nov 1;16(21):5329-38
pubmed: 20837694
Cancers (Basel). 2020 Jul 03;12(7):
pubmed: 32635216
Strahlenther Onkol. 2021 Mar;197(3):231-245
pubmed: 32588101